GB0001448D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0001448D0
GB0001448D0 GBGB0001448.0A GB0001448A GB0001448D0 GB 0001448 D0 GB0001448 D0 GB 0001448D0 GB 0001448 A GB0001448 A GB 0001448A GB 0001448 D0 GB0001448 D0 GB 0001448D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0001448.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0001448(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0001448.0A priority Critical patent/GB0001448D0/en
Publication of GB0001448D0 publication Critical patent/GB0001448D0/en
Priority to MYPI20010226A priority patent/MY155269A/en
Priority to CO01003434A priority patent/CO5261584A1/es
Priority to ES01905671T priority patent/ES2274865T5/es
Priority to HU0204156A priority patent/HUP0204156A3/hu
Priority to CA2396212A priority patent/CA2396212C/en
Priority to JP2001553825A priority patent/JP3978338B2/ja
Priority to PT01905671T priority patent/PT1248804E/pt
Priority to DE60124863T priority patent/DE60124863T3/de
Priority to AU33697/01A priority patent/AU772949B2/en
Priority to CN018039529A priority patent/CN1395581B/zh
Priority to HK03102022.5A priority patent/HK1050013A1/zh
Priority to ARP010100247A priority patent/AR027253A1/es
Priority to US10/181,324 priority patent/US20030124617A1/en
Priority to CZ20022531A priority patent/CZ302738B6/cs
Priority to PE2001000065A priority patent/PE20011219A1/es
Priority to RU2002121649/13A priority patent/RU2264413C2/ru
Priority to SK1035-2002A priority patent/SK288054B6/sk
Priority to NZ519936A priority patent/NZ519936A/en
Priority to AT01905671T priority patent/ATE346868T1/de
Priority to BR0107661-2A priority patent/BR0107661A/pt
Priority to KR1020027009374A priority patent/KR100697126B1/ko
Priority to DK01905671.2T priority patent/DK1248804T4/da
Priority to SI200130698T priority patent/SI1248804T2/sl
Priority to TR2002/01780T priority patent/TR200201780T2/xx
Priority to EP01905671A priority patent/EP1248804B2/en
Priority to MXPA02007091A priority patent/MXPA02007091A/es
Priority to PCT/EP2001/000591 priority patent/WO2001053353A2/en
Priority to PL356297A priority patent/PL207642B1/pl
Priority to IL15055101A priority patent/IL150551A0/xx
Priority to IL150551A priority patent/IL150551A/en
Priority to NO20023266A priority patent/NO329816B1/no
Priority to ZA2002/05659A priority patent/ZA200205659B/en
Priority to US11/484,472 priority patent/US7491392B2/en
Priority to CY20061101860T priority patent/CY1107989T1/el
Priority to JP2007000148A priority patent/JP2007097598A/ja
Priority to US12/351,007 priority patent/US20090232803A1/en
Priority to US13/044,918 priority patent/US20110182894A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
GBGB0001448.0A 2000-01-21 2000-01-21 Organic compounds Ceased GB0001448D0 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds
MYPI20010226A MY155269A (en) 2000-01-21 2001-01-18 ANTIBODIES TO HUMAN IL-1ß
CO01003434A CO5261584A1 (es) 2000-01-21 2001-01-18 Anticuerpos para il-1 humana
PL356297A PL207642B1 (pl) 2000-01-21 2001-01-19 Przeciwciało wiążące IL-1ß, konstrukt DNA, wektor ekspresyjny, kompozycja farmaceutyczna, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
IL15055101A IL150551A0 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
SK1035-2002A SK288054B6 (sk) 2000-01-21 2001-01-19 Antibody to IL-1 beta, IL-1 beta binding molecule, its use and process for production, first DNA construct, expression vector and pharmaceutical composition
BR0107661-2A BR0107661A (pt) 2000-01-21 2001-01-19 Anticorpos para il-1/ß humana
CA2396212A CA2396212C (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
JP2001553825A JP3978338B2 (ja) 2000-01-21 2001-01-19 ヒトＩＬ−１βに対する抗体
PT01905671T PT1248804E (pt) 2000-01-21 2001-01-19 Anticorpos contra il-1b humana
DE60124863T DE60124863T3 (de) 2000-01-21 2001-01-19 Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
AU33697/01A AU772949B2 (en) 2000-01-21 2001-01-19 Antibodies to human IL-1beta
CN018039529A CN1395581B (zh) 2000-01-21 2001-01-19 重组人白细胞介素-1β抗体
HK03102022.5A HK1050013A1 (zh) 2000-01-21 2001-01-19 抗人IL-1β抗體
ARP010100247A AR027253A1 (es) 2000-01-21 2001-01-19 Anticuerpos para il-1beta humana
US10/181,324 US20030124617A1 (en) 2000-01-21 2001-01-19 Antibodies to human il 1-beta
CZ20022531A CZ302738B6 (cs) 2000-01-21 2001-01-19 Protilátka proti IL-1beta tvorená molekulou vázající IL-1beta, tato molekula pro použití jako lécivo, použití této molekuly pro výrobu léciva, odpovídající DNA konstrukty a expresní vektor, zpusob prípravy uvedené molekuly a farmaceutická kompozice o
PE2001000065A PE20011219A1 (es) 2000-01-21 2001-01-19 ANTICUERPOS PARA IL-1ß HUMANA
RU2002121649/13A RU2264413C2 (ru) 2000-01-21 2001-01-19 РЕКОМБИНАНТНОЕ АНТИТЕЛО К ЧЕЛОВЕЧЕСКОМУ ИНТЕРЛЕЙКИНУ 1β
ES01905671T ES2274865T5 (es) 2000-01-21 2001-01-19 Anticuerpos recombinantes para la interleuquina-1 beta humana.
NZ519936A NZ519936A (en) 2000-01-21 2001-01-19 Antibodies to human Interleukin-1
AT01905671T ATE346868T1 (de) 2000-01-21 2001-01-19 Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
HU0204156A HUP0204156A3 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
KR1020027009374A KR100697126B1 (ko) 2000-01-21 2001-01-19 인간 ＩＬ-1β에 대한 항체
DK01905671.2T DK1248804T4 (da) 2000-01-21 2001-01-19 Rekombinante antistoffer mod humant interleukin-1-beta
SI200130698T SI1248804T2 (sl) 2000-01-21 2001-01-19 Rekombinantna protitelesa usmerjena proti humanemu interlevkinu-1 beta
TR2002/01780T TR200201780T2 (tr) 2000-01-21 2001-01-19 İnsanlara özgü interlökin-1 beta' ya karşı rekombinant antikorlar
EP01905671A EP1248804B2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
MXPA02007091A MXPA02007091A (es) 2000-01-21 2001-01-19 Anticuerpos para il-1b humana.
PCT/EP2001/000591 WO2001053353A2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interkleukin-1 beta
IL150551A IL150551A (en) 2000-01-21 2002-07-02 Recombinant antibody against interleukin - 1 human beta, pharmaceutical compounds that include it, a construct of DNA that encodes it, a process for its preparation and uses in drug preparation
NO20023266A NO329816B1 (no) 2000-01-21 2002-07-05 Antistoffer mot humant IL-10, anvendelse av disse, DNA konstruksjoner, ekspresjonsvektor, fremgangsmate for fremstilling og farmasoytisk sammensetning
ZA2002/05659A ZA200205659B (en) 2000-01-21 2002-07-16 Recombinant antibodies to human interleukin-1 beta
US11/484,472 US7491392B2 (en) 2000-01-21 2006-07-11 Antibodies to human IL-1β
CY20061101860T CY1107989T1 (el) 2000-01-21 2006-12-29 Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα
JP2007000148A JP2007097598A (ja) 2000-01-21 2007-01-04 ヒトＩＬ−１βに対する抗体
US12/351,007 US20090232803A1 (en) 2000-01-21 2009-01-09 Antibodies to human il-1beta
US13/044,918 US20110182894A1 (en) 2000-01-21 2011-03-10 Methods of treating diabetes using IL-1beta antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds

Publications (1)

Publication Number Publication Date
GB0001448D0 true GB0001448D0 (en) 2000-03-08

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0001448.0A Ceased GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds

Country Status (33)

Country Link
US (4) US20030124617A1 (https=)
EP (1) EP1248804B2 (https=)
JP (2) JP3978338B2 (https=)
KR (1) KR100697126B1 (https=)
CN (1) CN1395581B (https=)
AR (1) AR027253A1 (https=)
AT (1) ATE346868T1 (https=)
AU (1) AU772949B2 (https=)
BR (1) BR0107661A (https=)
CA (1) CA2396212C (https=)
CO (1) CO5261584A1 (https=)
CY (1) CY1107989T1 (https=)
CZ (1) CZ302738B6 (https=)
DE (1) DE60124863T3 (https=)
DK (1) DK1248804T4 (https=)
ES (1) ES2274865T5 (https=)
GB (1) GB0001448D0 (https=)
HK (1) HK1050013A1 (https=)
HU (1) HUP0204156A3 (https=)
IL (2) IL150551A0 (https=)
MX (1) MXPA02007091A (https=)
MY (1) MY155269A (https=)
NO (1) NO329816B1 (https=)
NZ (1) NZ519936A (https=)
PE (1) PE20011219A1 (https=)
PL (1) PL207642B1 (https=)
PT (1) PT1248804E (https=)
RU (1) RU2264413C2 (https=)
SI (1) SI1248804T2 (https=)
SK (1) SK288054B6 (https=)
TR (1) TR200201780T2 (https=)
WO (1) WO2001053353A2 (https=)
ZA (1) ZA200205659B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2474616A1 (en) * 2002-01-28 2003-08-07 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
ATE491953T1 (de) * 2003-09-15 2011-01-15 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
DK2270045T3 (en) 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
EP2361933A3 (en) * 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
HUE029021T2 (en) * 2005-06-21 2017-02-28 Xoma (Us) Llc IL-1beta-binding antibodies and fragments thereof
PL1940465T3 (pl) * 2005-10-26 2013-01-31 Novartis Ag Nowe zastosowanie przeciwciał anty-IL-1beta
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
EP2114443A4 (en) * 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
CN104873972A (zh) * 2007-05-29 2015-09-02 诺华股份有限公司 抗IL-1β治疗的新适应症
SI2391650T1 (sl) 2007-12-20 2015-03-31 Xoma (Us) Llc Postopki za zdravljenje protina
CA2727171A1 (en) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
JP2012502058A (ja) 2008-09-05 2012-01-26 ゾーマ テクノロジー リミテッド β細胞機能の改善のための方法
SI2493922T1 (sl) 2009-10-26 2017-06-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
BR112012028557A2 (pt) 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
ME02106B (me) * 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
SG10201605675WA (en) 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
LT2814843T (lt) 2012-02-13 2020-09-25 Agency For Science, Technology And Research ŽMOGAUS MONOKLONINIAI ANTIKŪNAI, NEUTRALIZUOJANTYS IL-1ß
ME03551B (me) 2012-06-12 2020-07-20 Regeneron Pharma Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
CN110818793A (zh) 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN116063489B (zh) * 2022-10-21 2026-01-30 杭州靶向食品科技有限公司 一种治疗痛风的单克隆抗体及其相应的组合物
CN121511262A (zh) 2023-06-28 2026-02-10 北京哲源科技有限责任公司 靶向pd-l1和il-1的双特异性抗体及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ES2274865T3 (es) 2007-06-01
MXPA02007091A (es) 2002-12-13
CA2396212A1 (en) 2001-07-26
JP2003520595A (ja) 2003-07-08
RU2002121649A (ru) 2004-03-10
US7491392B2 (en) 2009-02-17
AU3369701A (en) 2001-07-31
IL150551A0 (en) 2003-02-12
US20090232803A1 (en) 2009-09-17
CO5261584A1 (es) 2003-03-31
DK1248804T4 (da) 2010-04-06
SK10352002A3 (sk) 2003-03-04
KR100697126B1 (ko) 2007-03-20
SK288054B6 (sk) 2013-03-01
US20030124617A1 (en) 2003-07-03
AR027253A1 (es) 2003-03-19
PE20011219A1 (es) 2001-12-17
JP2007097598A (ja) 2007-04-19
HUP0204156A2 (hu) 2003-03-28
US20060251660A1 (en) 2006-11-09
HK1050013A1 (zh) 2003-06-06
WO2001053353A3 (en) 2002-04-04
EP1248804B1 (en) 2006-11-29
PL207642B1 (pl) 2011-01-31
CN1395581A (zh) 2003-02-05
JP3978338B2 (ja) 2007-09-19
CZ302738B6 (cs) 2011-10-12
DE60124863D1 (de) 2007-01-11
NO20023266D0 (no) 2002-07-05
CY1107989T1 (el) 2013-09-04
MY155269A (en) 2015-09-30
BR0107661A (pt) 2002-11-19
AU772949B2 (en) 2004-05-13
DE60124863T2 (de) 2007-04-26
PT1248804E (pt) 2007-02-28
ATE346868T1 (de) 2006-12-15
KR20020073178A (ko) 2002-09-19
NO329816B1 (no) 2010-12-27
IL150551A (en) 2010-11-30
DK1248804T3 (da) 2007-02-26
SI1248804T1 (sl) 2007-06-30
WO2001053353A2 (en) 2001-07-26
DE60124863T3 (de) 2010-05-20
PL356297A1 (en) 2004-06-28
ZA200205659B (en) 2003-12-31
HUP0204156A3 (en) 2005-09-28
US20110182894A1 (en) 2011-07-28
TR200201780T2 (tr) 2003-01-21
CN1395581B (zh) 2010-10-13
NZ519936A (en) 2004-02-27
CZ20022531A3 (cs) 2002-10-16
EP1248804B2 (en) 2009-12-02
ES2274865T5 (es) 2010-04-19
CA2396212C (en) 2013-04-02
RU2264413C2 (ru) 2005-11-20
NO20023266L (no) 2002-08-28
SI1248804T2 (sl) 2010-04-30
EP1248804A2 (en) 2002-10-16

Similar Documents

Publication Publication Date Title
AU8389101A (en) Organic compounds
GB0010955D0 (en) Organic compounds
GB0006398D0 (en) Organic compounds
GB0003111D0 (en) Organic compounds
GB0001448D0 (en) Organic compounds
GB0008694D0 (en) Organic compounds
GB0008785D0 (en) Organic compounds
GB0002100D0 (en) Organic compounds
AU3458802A (en) Organic compounds
GB0007108D0 (en) Organic compounds
GB0007911D0 (en) Organic compounds
GB0002740D0 (en) Organic compounds
GB0009037D0 (en) Organic compounds
GB0009054D0 (en) Organic compounds
GB0010200D0 (en) Organic compounds
GB0009053D0 (en) Organic compounds
GB0009055D0 (en) Organic compounds
GB0010205D0 (en) Organic compounds
GB0010211D0 (en) Organic compounds
GB0003265D0 (en) Organic compounds
GB0009899D0 (en) Organic compounds
GB0003268D0 (en) organic compounds
GB0010203D0 (en) Organic compounds
GB0010204D0 (en) Organic compounds
GB0006735D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)